ISBN: Table 87: Clinical evidence summary: NP monitoring versus clinical monitoring in people who also have chronic kidney disease Outcomes No of Participant s (studies) Follow up Quality of the evidence (GRADE) Relativ e effect CI) Anticipated absolute effects Risk with Clinical monitoring Risk difference with NP monitoring All-cause mortality 1147 months VERY LOW b,c,e due to risk of bias, imprecision, inconsistency Approximatea (from 105 fewer to 172 more) All-cause hospitalisation (days in hospital) VERY LOWb,c,d due to risk of bias, imprecision, indirectness The mean all-cause hospitalisation (days in hospital) in the control group was 6.54 days in hospital The mean all-cause hospitalisation (days in hospital) in the intervention groups was (2.81 lower to 3.57 higher) a Control group risk not available, approximated from risk for both arms combined, will under-estimate effect b Downgraded by 1 increment if the majority of the evidence was at high risk of bias, and downgraded by 2 increments if the majority of the evidence was at very high risk of bias c Downgraded by 1 increment if the confidence interval crossed one MID or by 2 increments if the confidence interval crossed both MIDs d Downgraded by 1 increment for indirectness as proxy for the protocol outcome of rate ratio of all-cause admissions e Downgraded by 1 increment as point estimates were inconsistent, not enough studies to perform subgroup analysis, I2 Chronic Heart Failure Monitoring NICE 2018. All rights reserved. Subject to Notice of rights. ISBN: 978-1-4731-3093-7 8.2.4 Economic evidence Published literature No previously published economic evidence was identified for this question in the review. 